30-Second Takeaway
- Low‑dose IL‑2 reduced Behçet’s oral ulcers and pain without excess serious adverse events via Treg expansion.
- VAERS data show no disproportionate reporting of systemic autoimmune rheumatic diseases after COVID‑19 vaccination.
- Breathomics in SLE identified VOC signatures that discriminate disease and track activity and fatigue noninvasively.
Week ending January 10, 2026
Targeted pathways and risk signals to refine rheumatology care: IL‑2 for Behçet’s, IFN‑high LN, SSc‑ILD PD‑1 axis, and real‑world safety data
Low‑dose IL‑2 improves oral ulcers and quality of life in Behçet’s without added infections
This randomized double‑blind phase 2 trial enrolled 60 Behçet’s patients with active oral ulcers to low‑dose IL‑2 or placebo. At week 12, IL‑2 markedly reduced oral ulcer counts versus placebo (0.69 ± 1.05 vs 1.57 ± 0.90; P = 0.001). Ulcer pain, overall disease activity, and quality of life improved more in the IL‑2 arm. No infections or severe adverse events occurred in either group during follow‑up. IL‑2 expanded regulatory T cells and lowered the effector T cell:Treg ratio, supporting Treg‑directed therapy for Behçet’s oral disease.
VAERS disproportionality analysis finds no SARD safety signal after COVID‑19 vaccination
Using approximately 680,000 VAERS reports from 2020–2024, this study evaluated systemic autoimmune rheumatic disease reports after COVID‑19 vaccination. COVID‑19 vaccines were compared with all other vaccines using PRR, ROR, and Bayesian information component metrics for multiple named SARDs. No significant disproportional reporting signal emerged for polymyalgia rheumatica, giant cell arteritis, SLE, systemic sclerosis, Sjögren’s, myositis, or other vasculitides. Other vasculitides were reported less frequently after COVID‑19 vaccines than after non‑COVID vaccines. Sex‑stratified analyses were consistent, reinforcing a favorable autoimmune rheumatic safety profile while emphasizing continued post‑marketing surveillance.
Exhaled VOC signatures distinguish SLE and reflect disease activity, fatigue, and gut integrity
Investigators collected exhaled breath from 30 SLE patients and 30 matched controls using standardized sampling and untargeted GC‑MS. Of 1433 detected volatile compounds, 539 breath‑derived VOCs generated patterns that discriminated SLE from controls and stratified disease activity and fatigue. Methyl acetate was inversely associated with disease activity and fatigue, suggesting links to immune homeostasis. A cluster of branched alkenes and alcohols tracked active disease and higher fatigue, consistent with oxidative stress and lipid peroxidation biology. Nitrogen‑containing heterocycles displayed U‑shaped behavior across disease states, potentially signaling varying intestinal permeability. These data support breathomics as a noninvasive candidate biomarker for monitoring SLE activity and symptom burden pending validation.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.